Literature DB >> 11805133

Heparin cofactor II inhibits arterial thrombosis after endothelial injury.

Li He1, Cristina P Vicente, Randal J Westrick, Daniel T Eitzman, Douglas M Tollefsen.   

Abstract

Heparin cofactor II (HCII) is a plasma protein that inhibits thrombin rapidly in the presence of dermatan sulfate, heparan sulfate, or heparin. HCII has been proposed to regulate coagulation or to participate in processes such as inflammation, atherosclerosis, and wound repair. To investigate the physiologic function of HCII, about 2 kb of the mouse HCII gene, encoding the N-terminal half of the protein, was deleted by homologous recombination in embryonic stem cells. Crosses of F1 HCII(+/-) animals produced HCII(-/-) offspring at the expected mendelian frequency. Biochemical assays confirmed the absence of dermatan sulfate-dependent thrombin inhibition in the plasma of HCII(-/-) animals. Crosses of HCII(-/-) animals produced litters similar in size to those obtained from heterozygous matings. At 1 year of age, HCII-deficient animals were grossly indistinguishable from their wild-type littermates in weight and survival, and they did not appear to have spontaneous thrombosis or other morphologic abnormalities. In comparison with wild-type animals, however, they demonstrated a significantly shorter time to thrombotic occlusion of the carotid artery after photochemically induced endothelial cell injury. This abnormality was corrected by infusion of purified HCII but not ovalbumin. These observations suggest that HCII might inhibit thrombosis in the arterial circulation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11805133      PMCID: PMC150836          DOI: 10.1172/JCI13432

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Prothrombotic phenotype of protein Z deficiency.

Authors:  Z F Yin; Z F Huang; J Cui; R Fiehler; N Lasky; D Ginsburg; G J Broze
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Heparin cofactor II activity in plasma during pregnancy and oral contraceptive use.

Authors:  M Massouh; A Jatoi; E M Gordon; O D Ratnoff
Journal:  J Lab Clin Med       Date:  1989-12

3.  Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice.

Authors:  D T Eitzman; R J Westrick; E G Nabel; D Ginsburg
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

4.  Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque.

Authors:  R A Shirk; N Parthasarathy; J D San Antonio; F C Church; W D Wagner
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

5.  Chondroitin/dermatan sulfate proteoglycan in human fetal membranes. Demonstration of an antigenically similar proteoglycan in fibroblasts.

Authors:  M J Brennan; A Oldberg; M D Pierschbacher; E Ruoslahti
Journal:  J Biol Chem       Date:  1984-11-25       Impact factor: 5.157

6.  Hyperlipidemia promotes thrombosis after injury to atherosclerotic vessels in apolipoprotein E-deficient mice.

Authors:  D T Eitzman; R J Westrick; Z Xu; J Tyson; D Ginsburg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-07       Impact factor: 8.311

Review 7.  Thrombin signalling and protease-activated receptors.

Authors:  S R Coughlin
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

8.  Complete antithrombin deficiency in mice results in embryonic lethality.

Authors:  K Ishiguro; T Kojima; K Kadomatsu; Y Nakayama; A Takagi; M Suzuki; N Takeda; M Ito; K Yamamoto; T Matsushita; K Kusugami; T Muramatsu; H Saito
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

9.  Activation of heparin cofactor II by dermatan sulfate.

Authors:  D M Tollefsen; C A Pestka; W J Monafo
Journal:  J Biol Chem       Date:  1983-06-10       Impact factor: 5.157

10.  Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma.

Authors:  D M Tollefsen; D W Majerus; M K Blank
Journal:  J Biol Chem       Date:  1982-03-10       Impact factor: 5.157

View more
  27 in total

1.  Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis.

Authors:  Sassan HajMohammadi; Keiichi Enjyoji; Marc Princivalle; Patricia Christi; Miroslav Lech; David Beeler; Helen Rayburn; John J Schwartz; Samad Barzegar; Ariane I de Agostini; Mark J Post; Robert D Rosenberg; Nicholas W Shworak
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

2.  Proteolytic activation transforms heparin cofactor II into a host defense molecule.

Authors:  Martina Kalle; Praveen Papareddy; Gopinath Kasetty; Douglas M Tollefsen; Martin Malmsten; Matthias Mörgelin; Artur Schmidtchen
Journal:  J Immunol       Date:  2013-05-08       Impact factor: 5.422

Review 3.  Approaches to prevent bleeding associated with anticoagulants: current status and recent developments.

Authors:  Manu Thomas Kalathottukaren; Charles A Haynes; Jayachandran N Kizhakkedathu
Journal:  Drug Deliv Transl Res       Date:  2018-08       Impact factor: 4.617

4.  Glycosaminoglycan-binding properties and kinetic characterization of human heparin cofactor II expressed in Escherichia coli.

Authors:  Suryakala Sarilla; Sally Y Habib; Douglas M Tollefsen; David B Friedman; Diana R Arnett; Ingrid M Verhamme
Journal:  Anal Biochem       Date:  2010-07-27       Impact factor: 3.365

5.  Fluorescent reporters of thrombin, heparin cofactor II, and heparin binding in a ternary complex.

Authors:  Ingrid M Verhamme
Journal:  Anal Biochem       Date:  2011-12-06       Impact factor: 3.365

6.  Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice.

Authors:  Cristina P Vicente; Li He; Douglas M Tollefsen
Journal:  Blood       Date:  2007-09-18       Impact factor: 22.113

7.  A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.

Authors:  Yasin Kokoye; Ivan Ivanov; Qiufang Cheng; Anton Matafonov; S Kent Dickeson; Shauna Mason; Daniel J Sexton; Thomas Renné; Keith McCrae; Edward P Feener; David Gailani
Journal:  Thromb Res       Date:  2016-02-18       Impact factor: 3.944

8.  Sucrose octasulfate selectively accelerates thrombin inactivation by heparin cofactor II.

Authors:  Suryakala Sarilla; Sally Y Habib; Dmitri V Kravtsov; Anton Matafonov; David Gailani; Ingrid M Verhamme
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

9.  Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II.

Authors:  Li He; Tusar K Giri; Cristina P Vicente; Douglas M Tollefsen
Journal:  Blood       Date:  2008-02-15       Impact factor: 22.113

10.  Understanding Dermatan Sulfate-Heparin Cofactor II Interaction through Virtual Library Screening.

Authors:  Arjun Raghuraman; Philip D Mosier; Umesh R Desai
Journal:  ACS Med Chem Lett       Date:  2010-06-14       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.